2005
Automated Quantitative Analysis (AQUA) of In Situ Protein Expression, Antibody Concentration, and Prognosis
McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated Quantitative Analysis (AQUA) of In Situ Protein Expression, Antibody Concentration, and Prognosis. Journal Of The National Cancer Institute 2005, 97: 1808-1815. PMID: 16368942, DOI: 10.1093/jnci/dji427.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, NeoplasmBiomarkers, TumorCell Line, TumorConfidence IntervalsEnzyme-Linked Immunosorbent AssayFemaleFluorescent Antibody TechniqueGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunohistochemistryMaleMiddle AgedNeoplasmsOdds RatioPredictive Value of TestsPrognosisProtein Array AnalysisReceptor, ErbB-2Receptors, EstrogenSurvival AnalysisTreatment OutcomeTumor Suppressor Protein p53ConceptsDisease-specific mortalityHigh HER2 expressionHER2 expressionAntibody concentrationsHigh expressionPoor survivalRelative riskTissue microarrayCumulative disease-specific survivalBiomarker expressionLong-term survival dataLow expressionHER2 antibodyX-tile programDisease-specific survivalLow HER2 expressionKaplan-Meier methodBreast cancer patientsExpression of HER2Higher antibody concentrationsLow antibody concentrationsConcentration of antibodyCancer patientsPatient outcomesSitu protein expression
2003
ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.
Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J, Tallini G. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. Journal Of Clinical Oncology 2003, 21: 3226-35. PMID: 12947056, DOI: 10.1200/jco.2003.10.130.Peer-Reviewed Original ResearchConceptsThyroid carcinomaResult of diseasePoor prognosisRas mutationsTumor differentiationK-ras codon 13 mutationDifferentiated thyroid carcinomaCodon 13 mutationsAggressive cancer behaviorAggressive tumor phenotypeFollicular cell derivationN-ras mutationsClinicopathologic featuresIndependent predictorsUndifferentiated carcinomaThyroid cancerPoor survivalUndifferentiated tumorsPatientsCarcinomaActivating mutationsCancer behaviorSignificant associationTumorsRas tumors
2002
RET Activation and Clinicopathologic Features in Poorly Differentiated Thyroid Tumors
Santoro M, Papotti M, Chiappetta G, Garcia-Rostan G, Volante M, Johnson C, Camp RL, Pentimalli F, Monaco C, Herrero A, Carcangiu ML, Fusco A, Tallini G. RET Activation and Clinicopathologic Features in Poorly Differentiated Thyroid Tumors. The Journal Of Clinical Endocrinology & Metabolism 2002, 87: 370-379. PMID: 11788678, DOI: 10.1210/jcem.87.1.8174.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoma, PapillaryCell DifferentiationDrosophila ProteinsFemaleGene RearrangementHumansImmunohistochemistryLymphatic MetastasisMaleMiddle AgedOncogene Proteins, FusionPrognosisProtein-Tyrosine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-retReceptor Protein-Tyrosine KinasesReverse Transcriptase Polymerase Chain ReactionSurvival AnalysisThyroid NeoplasmsConceptsRET/PTC rearrangementsRET/PTCClinicopathologic parametersRET activationInsular growth patternRelevant clinicopathologic parametersClinical characteristicsClinicopathologic featuresDistant metastasisSignificant morbidityDifferentiated tumorsHistologic evidenceMale sexAnaplastic carcinomaPatient outcomesPoor survivalEpithelial neoplasmsPapillary carcinomaLow prevalenceOncocytic featuresThyroid tumorsSurvival analysisThyroid glandMorphologic featuresSame tumor